• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.

作者信息

Devlin H R, Boskovski L

机构信息

Toronto General Hospital.

出版信息

Drugs. 1988;35 Suppl 2:45-50. doi: 10.2165/00003495-198800352-00011.

DOI:10.2165/00003495-198800352-00011
PMID:3396488
Abstract

The synergistic interaction of cefotaxime and desacetylcefotaxime against 187 clinically significant anaerobic organisms was investigated. Fusobacterium nucleatum, Actinomyces odontolyticus, propionibacteria, lactobacilli, peptostreptococci, Streptococcus intermedius and Veillonella were sensitive to cefotaxime. Both Eubacterium lentum and Streptococcus morbillorum were resistant. The susceptibility of the clostridia varied from 0.125 to greater than 256 mg/L; only 20% of species demonstrated synergy between cefotaxime and desacetylcefotaxime. The minimum inhibitory concentration (MIC) of cefotaxime against members of the genus Bacteroides ranged from 0.0625 to greater than 256 mg/L. The MIC50 of cefotaxime to Bacteroides fragilis and B. vulgatus was lowered from 6 and 4 mg/L, respectively, to 2 and 1 mg/L, respectively, when 4 mg/L desacetylcefotaxime was added to the medium. Full or partial synergy was demonstrated by 50.7% of the Bacteroides species tested. While cefotaxime and desacetylcefotaxime act synergistically against many members of the genus Bacteroides, the MIC of at least 10% of strains is not affected by this combination.

摘要

相似文献

1
The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.
Drugs. 1988;35 Suppl 2:45-50. doi: 10.2165/00003495-198800352-00011.
2
The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):37S-46S.
3
Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):45-50. doi: 10.1016/0732-8893(89)90045-x.
4
Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):33-7. doi: 10.1016/0732-8893(89)90043-6.
5
In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):47S-53S.
6
Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.琼脂稀释法、微量稀释法和纸片洗脱法测定头孢噻肟及其代谢产物对厌氧菌协同作用的比较
J Clin Microbiol. 1986 Jun;23(6):1104-8. doi: 10.1128/jcm.23.6.1104-1108.1986.
7
Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S374-8. doi: 10.1093/clinids/4.supplement_2.s374.
8
The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs.
J Antimicrob Chemother. 1984 Sep;14 Suppl B:39-43. doi: 10.1093/jac/14.suppl_b.39.
9
Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms.
Diagn Microbiol Infect Dis. 1989 Mar-Apr;12(2):165-70. doi: 10.1016/0732-8893(89)90008-4.
10
A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus.
Am J Surg. 1992 Oct;164(4A Suppl):24S-27S. doi: 10.1016/s0002-9610(06)80054-1.

引用本文的文献

1
Empyema thoracis and lung abscess due to Gemella morbillorum.
Eur J Clin Microbiol Infect Dis. 1996 Jan;15(1):75-7. doi: 10.1007/BF01586189.

本文引用的文献

1
An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics.一种用于抗生素细菌敏感性常规检测的接种物复制装置。
Antibiot Chemother (Northfield). 1959 May;9(5):307-11.
2
Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.核酸衍生物拮抗剂。VIII. 生物化学相关抗代谢物组合中的协同作用。
J Biol Chem. 1954 Jun;208(2):477-88.
3
Preparing inoculum for susceptibility testing of anaerobes.制备用于厌氧菌药敏试验的接种物。
J Clin Microbiol. 1984 Mar;19(3):321-5. doi: 10.1128/jcm.19.3.321-325.1984.
4
The use of cefotaxime in a community hospital.头孢噻肟在社区医院的使用情况。
Drug Intell Clin Pharm. 1984 Feb;18(2):144-7. doi: 10.1177/106002808401800211.
5
The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S379-91. doi: 10.1093/clinids/4.supplement_2.s379.
6
Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S300-15. doi: 10.1093/clinids/4.supplement_2.s300.
7
Human metabolism of cefotaxime.头孢噻肟的人体代谢
J Antimicrob Chemother. 1980 Sep;6 Suppl A:93-101. doi: 10.1093/jac/6.suppl_a.93.
8
In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):47S-53S.
9
The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):37S-46S.
10
Antimicrobial activity of HR810 against 419 strict anaerobic bacteria.HR810对419株严格厌氧菌的抗菌活性。
Antimicrob Agents Chemother. 1985 Mar;27(3):413-5. doi: 10.1128/AAC.27.3.413.